At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
CARTISTEM®biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of Safety and Exploratory Efficacy of CARTISTEM®, a Cell Therapy Product for Articular Cartilage Defects: A Phase I/IIa Clinical Trial in Patients With Focal, Full-thickness Grade 3-4 Articular Cartilage Defects of the Knee
In Brief
A Phase 2 clinical trial evaluating CARTISTEM® for Degeneration Articular Cartilage Knee. Completed, enrolled 12 participants across 2 sites.
Detailed Summary
The purpose of this study is to determine whether CARTISTEM, a cell therapeutic product, is safe and effective in the treatment of articular cartilage defects of the knee as a result of ageing, trauma, or degenerative diseases.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDegeneration Articular Cartilage Knee
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 2012
Enrollment StartJan 2013
Primary CompletionJun 2017
Study CompletionAug 2017
TodayJul 2026
First PostedNov 26, 2012
Enrollment StartJan 7, 2013
Primary CompletionJun 2, 2017
Study CompletionAug 29, 2017
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 13.6 years ago
Interventions
CARTISTEM®biological